(VIANEWS) – Xcel Energy (XEL), Pembina Pipeline (PBA), Agree Realty Corporation (ADC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Xcel Energy (XEL)
21.9% sales growth and 10.33% return on equity
Xcel Energy Inc., through its subsidiaries, engages in the generation, purchasing, transmission, distribution, and sale of electricity. It operates through Regulated Electric Utility, Regulated Natural Gas Utility, and All Other segments. The company generates electricity through wind, nuclear, hydroelectric, biomass, and solar energy sources, as well as coal, natural gas, oil, wood, and refuse-derived fuels. It also purchases, transports, distributes, and sells natural gas to retail customers, as well as transports customer-owned natural gas. In addition, the company develops and leases natural gas pipelines, and storage and compression facilities; and invests in rental housing projects and nonregulated assets, as well as procures equipment for the construction of renewable generation facilities. It serves residential, commercial, and industrial customers in the portions of Colorado, Michigan, Minnesota, New Mexico, North Dakota, South Dakota, Texas, and Wisconsin. The company was incorporated in 1909 and is headquartered in Minneapolis, Minnesota.
Earnings Per Share
As for profitability, Xcel Energy has a trailing twelve months EPS of $3.21.
PE Ratio
Xcel Energy has a trailing twelve months price to earnings ratio of 16.74. Meaning, the purchaser of the share is investing $16.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.33%.
Sales Growth
Xcel Energy’s sales growth is 107.9% for the present quarter and 21.9% for the next.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Mar 14, 2024, the estimated forward annual dividend rate is 2.19 and the estimated forward annual dividend yield is 4.29%.
Moving Average
Xcel Energy’s value is below its 50-day moving average of $58.71 and way under its 200-day moving average of $60.15.
Revenue Growth
Year-on-year quarterly revenue growth declined by 15.1%, now sitting on 14.21B for the twelve trailing months.
2. Pembina Pipeline (PBA)
15.7% sales growth and 11.24% return on equity
Pembina Pipeline Corporation provides energy transportation and midstream services. It operates through three segments: Pipelines, Facilities, and Marketing & New Ventures. The Pipelines segment operates conventional, oil sands and heavy oil, and transmission assets with a transportation capacity of 2.9 millions of barrels of oil equivalent per day, the ground storage capacity of 10 millions of barrels, and rail terminalling capacity of approximately 105 thousands of barrels of oil equivalent per day serving markets and basins across North America. The Facilities segment offers infrastructure that provides customers with natural gas, condensate, and natural gas liquids (NGLs), including ethane, propane, butane, and condensate; and includes 354 thousands of barrels per day of NGL fractionation capacity, 21 millions of barrels of cavern storage capacity, and associated pipeline, and rail terminalling facilities and a liquefied propane export facility. The Marketing & New Ventures segment buys and sells hydrocarbon liquids and natural gas originating in the Western Canadian sedimentary basin and other basins. Pembina Pipeline Corporation was incorporated in 1954 and is headquartered in Calgary, Canada.
Earnings Per Share
As for profitability, Pembina Pipeline has a trailing twelve months EPS of $2.2.
PE Ratio
Pembina Pipeline has a trailing twelve months price to earnings ratio of 16.06. Meaning, the purchaser of the share is investing $16.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.24%.
3. Agree Realty Corporation (ADC)
14.1% sales growth and 3.47% return on equity
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of June 30, 2020, the Company owned and operated a portfolio of 936 properties, located in 46 states and containing approximately 18.4 million square feet of gross leasable area. The common stock of Agree Realty Corporation is listed on the New York Stock Exchange under the symbol "ADC".
Earnings Per Share
As for profitability, Agree Realty Corporation has a trailing twelve months EPS of $1.7.
PE Ratio
Agree Realty Corporation has a trailing twelve months price to earnings ratio of 33.31. Meaning, the purchaser of the share is investing $33.31 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.47%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Agree Realty Corporation’s EBITDA is 15.38.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Mar 27, 2024, the estimated forward annual dividend rate is 2.96 and the estimated forward annual dividend yield is 5.23%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 4.5% and 15%, respectively.
4. UNIVERSAL INSURANCE HOLDINGS (UVE)
11.2% sales growth and 21.24% return on equity
Universal Insurance Holdings, Inc., together with its subsidiaries, operates as an integrated insurance holding company in the United States. It develops, markets, and underwrites insurance products for personal residential insurance, such as homeowners, renters/tenants, condo unit owners, and dwelling/fire; and offers allied lines, coverage for other structures, and personal property, liability, and personal articles coverages. The company also advises on actuarial issues, oversees distribution, administers claims payments, performs policy administration and underwriting, and assists with reinsurance negotiations; places and manages reinsurance programs for the insurance entities; and operates Clovered.com, a digital agency for carrier partners and utilization of digital applications for adjusting claims. It offers its products through a network of independent agents, as well as direct-to-consumer online solutions, including digital insurance agency. The company was formerly known as Universal Heights, Inc. and changed its name to Universal Insurance Holdings, Inc. in January 2001. Universal Insurance Holdings, Inc. was incorporated in 1990 and is headquartered in Fort Lauderdale, Florida.
Earnings Per Share
As for profitability, UNIVERSAL INSURANCE HOLDINGS has a trailing twelve months EPS of $2.22.
PE Ratio
UNIVERSAL INSURANCE HOLDINGS has a trailing twelve months price to earnings ratio of 8.88. Meaning, the purchaser of the share is investing $8.88 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.24%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.7%, now sitting on 1.39B for the twelve trailing months.
5. NetEase (NTES)
10.4% sales growth and 24.78% return on equity
NetEase, Inc. engages in online games, music streaming, online intelligent learning services, and internet content services businesses in China and internationally . The company operates through Games and Related Value-Added Services, Youdao, Cloud Music, and Innovative Businesses and Others segments. It develops and operates PC and mobile games, as well as offers games licensed from other game developers. The company's products and services include Youdao Dictionary, an online knowledge tool; Youdao Translation, a tool specifically designed to support translation needs of business and leisure travelers; U-Dictionary, an online dictionary and translation app; Youdao Kids' Dictionary, a smart and fun tool; smart devices, such as Youdao Dictionary Pen, Youdao Smart Learning Pad, Youdao Listening Pod, Youdao Smart Light, Youdao Pocket Translator, and Youdao Super Dictionary; online courses; interactive learning apps; and education digitalization solutions, such as Youdao Smart Learning Terminal, a device that automates paper-based homework processing; Youdao Smart Cloud, a cloud-based platform that allows third-party app developers, smart device brands, and manufacturers to the company's OCR capabilities; and Youdao Sports, a sports-centric educational system. Its products and services also include NetEase Cloud Music, a music streaming platform; Yanxuan, an e-commerce platform, which sells private label products; www.163.com portal and related mobile app, Wangyi Xinwen, which deliver information such as news, sports events, technology, fashion trends, and online entertainment; NetEase Mail, an email service; NetEase CC Live streaming, a live streaming platform with a focus on game broadcasting; and NetEase Pay, a payment platform. The company was formerly known as NetEase.com, Inc. and changed its name to NetEase, Inc. in March 2012. NetEase, Inc. was founded in 1997 and is headquartered in Hangzhou, the People's Republic of China.
Earnings Per Share
As for profitability, NetEase has a trailing twelve months EPS of $6.27.
PE Ratio
NetEase has a trailing twelve months price to earnings ratio of 16.5. Meaning, the purchaser of the share is investing $16.5 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.78%.
6. Merchants Bancorp (MBIN)
10% sales growth and 17.67% return on equity
Merchants Bancorp operates as the diversified bank holding company in the United States. It operates through Multi-family Mortgage Banking, Mortgage Warehousing, and Banking segments. The Multi-family Mortgage Banking segment engages in the mortgage banking, which originates and services government sponsored mortgages including bridge financing products to refinance, acquire, or reposition multi-family housing projects, and construction lending for multi-family and healthcare facilities; offers customized loan products for need-based skilled nursing facilities, independent living, assisted living, and memory care; and tax credit equity syndicator. Its Mortgage Warehousing segment funds agency eligible residential loans including origination, purchase, and sale in the secondary market, as well as commercial loans to non-depository financial institutions. The Banking segment offers a range of financial products and services to consumers and businesses, which includes retail banking, commercial lending, agricultural lending, retail and correspondent residential mortgage banking, and small business administration lending. Merchants Bancorp was founded in 1990 and is headquartered in Carmel, Indiana.
Earnings Per Share
As for profitability, Merchants Bancorp has a trailing twelve months EPS of $5.64.
PE Ratio
Merchants Bancorp has a trailing twelve months price to earnings ratio of 7.6. Meaning, the purchaser of the share is investing $7.6 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.67%.
7. Halozyme Therapeutics (HALO)
8.8% sales growth and 222.07% return on equity
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.1.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 19.09. Meaning, the purchaser of the share is investing $19.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 222.07%.
Sales Growth
Halozyme Therapeutics’s sales growth is 20.9% for the ongoing quarter and 8.8% for the next.
Yearly Top and Bottom Value
Halozyme Therapeutics’s stock is valued at $40.08 at 01:22 EST, way below its 52-week high of $45.00 and way higher than its 52-week low of $29.85.
Previous days news about Halozyme Therapeutics(HALO)
- According to Zacks on Thursday, 28 March, "Over the past month, Halozyme Therapeutics (HALO Quick QuoteHALO – Free Report) , a stock from the same industry, has gained 2.6%. "
- According to Zacks on Friday, 29 March, "Over the past month, Halozyme Therapeutics (HALO Quick QuoteHALO – Free Report) , a stock from the same industry, has gained 2.2%. "
